TREAT-NMD Advisory Committee for Therapeutics (TACT)

TREAT-NMD is a major European collaboration in the neuromuscular field established by funding from the European Union. The goal of TREAT-NMD is to create the infrastructure to ensure that the most promising new therapies reach patients as quickly as possible. Since the network was launched in January 2007, its focus has been on the development of tools that industry, clinicians, and scientists need to bring novel therapeutic approaches through preclinical development and into the clinic, and on establishing best-practice care for neuromuscular patients worldwide.

PPMD is providing funding for the TREAT-NMD Advisory Committee for Therapeutics (TACT) to help review promising drug candidates for Duchenne. This review committee is made up of volunteers with expertise in preclinical development (manufacturing, toxicology, pharmacodynamics and biodistribution, ADME) clinical development, regulatory compliance, and ethics. Committee members also have a deep understanding of the biology and clinical aspects of neuromuscular diseases.

PPMD encourages companies seeking funding for drug development projects to consider undergoing a TACT review.

Related links

Information about the TACT process (download)
Information about TACT membership